Literature DB >> 15638775

Voltage gated ion channels: targets for anticonvulsant drugs.

Adam C Errington1, Thomas Stöhr, George Lees.   

Abstract

Epilepsy is one of the most prevalent neurological syndromes in the world today. Epilepsy describes a group of brain disorders whose symptoms and causes are diverse and complicated, but all share a common behavioural manifestation: the seizure. Seizures result from the abnormal discharge of groups of neurons within the brain, usually within a focal point, that can result in the recruitment of large brain regions into epileptiform activity. Although the range of explanations for the development of seizures can be as varied as genetic composition to acute head trauma, the net result is often similar. The excitability of neurons is governed by the input they receive from their neighbours and the intrinsic excitability of the neuron. In this review we focus on elements that are crucial to determining the intrinsic excitability of neurons in the CNS, the voltage gated ion channels (VGICs). VGICs as well as being important for physiological function are critical in producing hyperexcitability such as that associated with seizure discharges. Many drugs routinely used in the clinical setting, as well as several novel experimental drugs, have shown interactions with VGICs that underpin, at least in part, their anticonvulsant action. We review the physiological roles of voltage gated ion channels that are selective for sodium, potassium and calcium conductance and attempt to highlight their role in the pathology of epilepsy. This is supplemented by the mechanisms of drug action at these important anticonvulsant targets for classical and clinically relevant compounds (e.g. phenytoin, ethosuximide) as well as some important second generation drugs (e.g. gabapentin, levetiracetam) and novel experimental agents (e.g. retigabine, losigamone, safinamide). We also briefly discuss the urgent need for new drugs in this arena and the potential of combinatorial methods and recombinant screening to identify leads.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15638775     DOI: 10.2174/1568026053386872

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  25 in total

1.  VOLTAGE-GATED CALCIUM CHANNELS ARE NOT AFFECTED BY THE NOVEL ANTI-EPILEPTIC DRUG LACOSAMIDE.

Authors:  Yuying Wang; Rajesh Khanna
Journal:  Transl Neurosci       Date:  2011-03       Impact factor: 1.757

2.  Chronic deficit in the expression of voltage-gated potassium channel Kv3.4 subunit in the hippocampus of pilocarpine-treated epileptic rats.

Authors:  Luis F Pacheco Otalora; Frank Skinner; Mauro S Oliveira; Bianca Farrell; Massoud F Arshadmansab; Tarun Pandari; Ileana Garcia; Leslie Robles; Gerardo Rosas; Carlos F Mello; Boris S Ermolinsky; Emilio R Garrido-Sanabria
Journal:  Brain Res       Date:  2010-10-21       Impact factor: 3.252

Review 3.  T-type calcium channel blockers as neuroprotective agents.

Authors:  Benjamin J Kopecky; Ruqiang Liang; Jianxin Bao
Journal:  Pflugers Arch       Date:  2014-02-25       Impact factor: 3.657

4.  Chimeric derivatives of functionalized amino acids and α-aminoamides: compounds with anticonvulsant activity in seizure models and inhibitory actions on central, peripheral, and cardiac isoforms of voltage-gated sodium channels.

Authors:  Robert Torregrosa; Xiao-Fang Yang; Erik T Dustrude; Theodore R Cummins; Rajesh Khanna; Harold Kohn
Journal:  Bioorg Med Chem       Date:  2015-04-11       Impact factor: 3.641

5.  Anti-epileptic drugs delay age-related loss of spiral ganglion neurons via T-type calcium channel.

Authors:  Debin Lei; Xia Gao; Philip Perez; Kevin K Ohlemiller; Chien-Chang Chen; Kevin P Campbell; Aizhen Yang Hood; Jianxin Bao
Journal:  Hear Res       Date:  2011-05-26       Impact factor: 3.208

6.  Merging the structural motifs of functionalized amino acids and alpha-aminoamides: compounds with significant anticonvulsant activities.

Authors:  Christophe Salomé; Elise Salomé-Grosjean; James P Stables; Harold Kohn
Journal:  J Med Chem       Date:  2010-05-13       Impact factor: 7.446

7.  Impact of Topiramate on Rat Phrenic Nerve-Hemidiaphragm Preparations.

Authors:  Cem İsmail Küçükali; Erdem Tüzün; Asiye Nurten
Journal:  Noro Psikiyatr Ars       Date:  2016-09-01       Impact factor: 1.339

Review 8.  Clinical Pharmacokinetics and Pharmacodynamics of Safinamide.

Authors:  Thomas Müller; Paul Foley
Journal:  Clin Pharmacokinet       Date:  2017-03       Impact factor: 6.447

9.  Identification of the benzyloxyphenyl pharmacophore: a structural unit that promotes sodium channel slow inactivation.

Authors:  Amber M King; Xiao-Fang Yang; Yuying Wang; Erik T Dustrude; Cindy Barbosa; Michael R Due; Andrew D Piekarz; Sarah M Wilson; Fletcher A White; Christophe Salomé; Theodore R Cummins; Rajesh Khanna; Harold Kohn
Journal:  ACS Chem Neurosci       Date:  2012-09-19       Impact factor: 4.418

10.  Neuroprotective effects of blockers for T-type calcium channels.

Authors:  Norelle C Wildburger; Avary Lin-Ye; Michelle A Baird; Debin Lei; Jianxin Bao
Journal:  Mol Neurodegener       Date:  2009-10-28       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.